to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Current strategies for treatment of relapsed/refractory multiple myeloma.
Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstr?m Macroglobulinemia.
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Proteasome Endopeptidase Complex